Peoples Hospital of Deyang
Peoples Hospital of Deyang
Liu L.,Fudan University |
Liu L.,Shanghai Medical College |
Xiang J.,Fudan University |
Xiang J.,Shanghai Medical College |
And 29 more authors.
International Journal of Oncology | Year: 2016
The prognosis for pancreatic cancer (PC) is poor; however, the timely and accurate treatment of this disease will significantly improve prognosis. Serum biomarkers involve noninvasive tests that facilitate the early detection of tumors, predict outcomes and assess responses to therapy, so that the patient can be continuously monitored and receive the most appropriate therapy. Studies have reported that cancer antigen (CA)125 [also known as mucin 16 (MUC16)] has functional significance in the tumorigenic, metastatic and drug resistant properties of PC. Our aim was to use this biomarker in the diagnosis, detection of metastasis, prognosis and in the monitoring of the treatment effects of PC. Members of the Chinese Study Group for Pancreatic Cancer (CSPAC) reviewed the literature on CA125/ MUC16 and developed an objective consensus on the clinical utility of CA125/MUC16 for PC. They confirmed the role of CA125/MUC16 in tumorigenesis and the progression of PC, and recommended monitoring CA125/MUC16 levels in all aspects of the diagnosis and treatment of PC, particularly those that involve the monitoring of treatments. In addition, they suggested that the combination of other biomarkers and imaging techniques, together with CA125/MUC16, would improve the accuracy of the clinical decision-making process, thereby facilitating the optimization of treatment strategies. Periodic clinical updates of the use of CA125/MUC16 have been established, which are important for further analyses and comparisons of clinical results from affiliates and countries, particularly as regards the in-depth biological function and clinical translational research of this biomarker.
Liu C.,Fudan University |
Chen R.,Sun Yat Sen University |
Chen Y.,Peking Union Medical College |
Fu D.,Fudan University |
And 20 more authors.
International Journal of Oncology | Year: 2015
Understanding and formulating an appropriate strategy for the para-aortic lymph nodes (LN16) during curative surgery for pancreatic head cancer have been controversial for some time. This study intended to provide a recommendation for surgeons to perform an optimal curative surgery on pancreatic cancer patients with or without LN16 involvement. Based on an updated literature search and review, the members of the Chinese Study Group for Pancreatic Cancer (CSPAC) from high-volume centers reached a consensus on the issue of LN16 in pancreatic head cancer. Metastasis to LN16 is quite.
Jin K.,Fudan University |
Xu J.,Fudan University |
Chen J.,Sun Yat Sen University |
Chen M.,Sun Yat Sen University |
And 50 more authors.
International Journal of Oncology | Year: 2016
Pancreatic neuroendocrine neoplasms (p-NENs) are slowly growing tumors with frequent liver metastasis. There is a variety of approaches to treat non-functional p-NENs with synchronous liver metastasis (LM) which complicates the determination of optimal treatment. Based on updated literature review, we discussed the treatment strategy determinants for p-NEN with LM. According to the resectability of primary tumor, the WHO 2010 grade classification and the radiological type of liver metastasis, the CSNET group reached agreements on a number of issues, including the following. Prior to treatment, biopsy is required to confirm pathology. Liver biopsy is important for more accurate grading of tumor and percutaneous core needle biopsy is more available than EUS-FNA. In patients with unresectable primary, surgical resection for liver-metastatic lesions should be avoided. Curative surgery is recommended for G1/G2 p-NET with type I LM and R1 resection also seems to improve overall survival rate. Cytoreductive surgery is recommended for G1/G2 p-NET with type II LM in select patients, and should meet stated requirements. Surgical resection for G1/G2 p-NET with type III LM and p-NEC with LM should be avoided, and insufficient evidence exists to guide the surgical treatment of G3 p-NET with LM. Liver transplantation may be an option in highly select patients. In addition, the optimal time for surgical approach is still required for more evidence.
Kuang P.,University of Sichuan |
Liu T.,University of Sichuan |
Pan L.,University of Sichuan |
Zhu H.,University of Sichuan |
And 19 more authors.
Leukemia and Lymphoma | Year: 2016
We report the clinical results of sustainedly integrating imatinib and interferon-α into maintenance therapy in the patients ineligible for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Maintenance therapy lasted for 5 years with imatinib 400 mg daily, interferon-α 3 million units, 2∼3 doses per week, and chemotherapy including vindesine and dexamethasone scheduled monthly in first year, once every 2 months in second year, and once every 3 months in third year. The chemotherapy was discontinued after 3 years and the imatinib and interferon-α continued for another 2 years. For 41 patients without allo-HSCT with a median follow-up of 32 months, the 3-year DFS and OS were 42.7 ± 8.6% and 57.9 ± 8.4%, respectively. Our study suggests that sustaining maintenance with low-dose chemotherapy, imatinib and interferon-α improved survival of adult Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) patients ineligible for allo-HSCT, and even provided an opportunity for cure. BCR/ABL persistent negativity at 6 and 9 months may have benefit to choose suitable patients for the imatinib/interferon-α maintenance strategy. © 2016 Taylor & Francis
PubMed | University of Sichuan, Central Hospital of Mianyang, Peoples Hospital of Deyang, the 3rd Peoples Hospital of Chengdu and the First Hospital of Liangshan
Type: Journal Article | Journal: Leukemia & lymphoma | Year: 2016
We report the clinical results of sustainedly integrating imatinib and interferon- into maintenance therapy in the patients ineligible for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Maintenance therapy lasted for 5 years with imatinib 400mg daily, interferon- 3 million units, 23 doses per week, and chemotherapy including vindesine and dexamethasone scheduled monthly in first year, once every 2 months in second year, and once every 3 months in third year. The chemotherapy was discontinued after 3 years and the imatinib and interferon- continued for another 2 years. For 41 patients without allo-HSCT with a median follow-up of 32 months, the 3-year DFS and OS were 42.78.6% and 57.98.4%, respectively. Our study suggests that sustaining maintenance with low-dose chemotherapy, imatinib and interferon- improved survival of adult Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) patients ineligible for allo-HSCT, and even provided an opportunity for cure. BCR/ABL persistent negativity at 6 and 9 months may have benefit to choose suitable patients for the imatinib/interferon- maintenance strategy.
Liu Y.-L.,Luzhou Medical College |
Liu Y.-L.,Peoples Hospital Of Deyang |
Li F.-B.,Peoples Hospital Of Deyang |
Zhao X.,Peoples Hospital Of Deyang
Chinese Journal of Tissue Engineering Research | Year: 2014
BACKGROUND: Wnt signal pathway is involved in the regulation of bone marrow mesenchymal stem cells differentiating into osteoblasts, promotes osteoblasts proliferation and differentiation, inhibits programmed death of osteoblasts, and indirectly affects the function of osteoclasts. OBJECTIVE: To summarize the relationship between Wnt/β-catenin signal pathway and bone disease. METHODS: A computer-based online search was performed to find papers published between January 2000 and January 2014 in CNKI database and Elsevier database. The key words were “Wnt/β-catenin, osteoblasts, bone marrow mesenchymal stem cells, osteoarthritis, chondrocytes” in Chinese. Documents concerning the effects of Wnt/β-catenin signal pathway on osteoblasts and bone disease were included. RESULTS AND CONCLUSION: Wnt signaling pathway is consisted of Wnt/β-catenin signal pathway (Wnt typical signal pathway), Wnt/Ca2+ signal pathway and Wnt/planar cell polarity signal pathway. Wnt signaling pathway is one of the most important regulatory systems that plays a key role in modulating the differentiation, proliferation and programmed cell death of osteoblasts, osteoclasts and chondrocytes. The role of Wnt signal pathway in patients with rheumatoid arthritis is mediated by osteoblasts. The inhibitory factor of Wnt signal pathway in osteoblasts is upregulated, which reduces the ratio of osteoprotegerin/receptor activating factor ligand, promotes the osteoclasts differentiation and immaturation. The researches addressing the components and effect of Wnt signal pathway are important for the special treatment of bone diseases and the prevention of osteoporosis or other bone diseases. © 2014, Journal of Clinical Rehabilitative Tissue Engineering Research. All Rights Reserved.